Esperion loss grows as sales effort ramps up
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a loss of $90.8 million or $3.50 a share in the first quarter ended March 31, vs. a loss of $78.2 million or …
Esperion secures $50M in financing
ANN ARBOR—Esperion Therapeutics (NASDAQ: ESPR), developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide …
Esperion expands licensing deal with Daiichi Sankyo Group
Esperion expands partnership with Daiichi Sankyo Group ANN ARBOR–Esperion Therapeutics (NASDAQ: ESPR), developers of a new class of cholesterol-lowering drugs, announced it has entered into a licensing agreement with Daiichi …
Nexletol combo cuts bad cholesterol 60.5 percent in new study
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based developer of cholesterol-lowering drugs, announced that the results of a Phase 2 study evaluating the combination of its Nexletol (bempedoic acid) …
Esperion posts big loss, but sales of its drugs rising rapidly
ANN ARBOR—Esperion Therapeutics Inc. reported a 150 percent increase in sales for its new cholesterol-lowering drug between the third quarter and the fourth quarter ended Dec. 31. Overall, the company …
MMS joins decentralized clinical trial alliance
CANTON TWP.–MMS Holdings, a contract research organization for the pharmaceutical industry, has joined the Decentralized Trials and Research Alliance, an organization launched in December to unite healthcare companies, regulators, patient …
Esperion targets another cholesterol-buster
ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …
Esperion appoints new COO; commercial officer leaves
ANN ARBOR—Esperion Therapeutics Inc. has named veteran cardiovascular pharmaceutical industry executive Sheldon Koenig as its chief operating officer. Koenig will report to president and CEO Tim M. Mayleben. In this …
Esperion loss grows as company begins selling cholesterol-fighting drugs
ANN ARBOR—Esperion Therapeutics Inc. reported a loss of $85.4 million or $3.07 a share in the third quarter of 2020, vs. a loss of $68.4 million or $2.52 a share …
Developments in GR, Romulus, TC get state support
LANSING—The board of the Michigan Strategic Fund has approved state aid for two business expansions and a community project that will generate a total of $154.7 million in capital investment …